Sylvain Thépot, Raphael Itzykson, Valerie Seegers, Christian Recher, Emmanuel Raffoux, Bruno Quesnel, Jacques Delaunay, Thomas Cluzeau, Anne Marfaing Koka, Aspasia Stamatoullas, Marie-Pierre Chaury, Caroline Dartigeas, Stéphane Cheze, Anne Banos, Pierre Morel, Isabelle Plantier, Anne-Laure Taksin, Jean Pierre Marolleau, Cecile Pautas, Xavier Thomas, Francoise Isnard, Blandine Beve, Yasmine Chait, Agnes Guerci, Norbert Vey, Francois Dreyfus, Lionel Ades, Norbert Ifrah, Herve Dombret, Pierre Fenaux, Claude Gardin
Limited data are available on azacitidine (AZA) treatment and its prognostic factors in acute myeloid leukemia (AML). One hundred and forty-nine previously untreated AML patients considered ineligible for intensive chemotherapy received AZA in a compassionate patient-named program. AML diagnosis was de novo, post-myelodysplastic syndromes (MDS), post-MPN, and therapy-related AML in 51, 55, 13, and 30 patients, respectively. Median age was 74 years, median white blood cell count (WBC) was 3.2 × 10⁹ /L and 58% of the patients had ≥ 30% marrow blasts...
April 2014: American Journal of Hematology